2-(吡咯烷-3-基)噻唑 | 630121-89-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(吡咯烷-3-基)噻唑
• 英文名称: 2-pyrrolidin-3-yl-1,3-thiazole
• 英文别名: 2-(Pyrrolidin-3-yl)thiazole
• CAS: 630121-89-0
• 化学式: C₇H₁₀N₂S
• mdl: MFCD10000581
• 分子量: 154.236
• InChiKey: AKESXMXWTJZWLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(thiophen-2-yl)pyrrolidine 、 1,3-Thiazol-2-yl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester 以to give 2-pyrrolidin-3-yl-thiazole的产率得到2-(吡咯烷-3-基)噻唑
  参考文献：
  名称：

  Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections

  摘要：

  提供了某些化学实体、制药组合物和治疗方法，用于治疗黄病毒科的成员，例如丙型肝炎病毒（丙肝或HCV）。

  公开号：

  US20120121540A1

文献信息

• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• [EN] NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PDE10
  申请人：AMGEN INC

  公开号：WO2011143365A1

  公开（公告）日：2011-11-17

  Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物：(I)，如规范中定义的，含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10治疗可治疗的疾病或疾病的方法，如肥胖症、亨廷顿病、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症等。
• [EN] CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] CERTAINS INHIBITEURS DE KYNURÉNINE-3-MONO-OXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DOMINGUEZ CELIA

  公开号：WO2013016488A1

  公开（公告）日：2013-01-31

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用可接受载体的制药组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的量，以减少疾病或疾病的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化学实体作为活性剂或与一种或多种其他治疗剂结合使用至少一种化学实体。还提供了筛选具有抑制KMO活性能力的化合物的方法。
• UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS
  申请人：ALLEN Jennifer R.

  公开号：US20110306587A1

  公开（公告）日：2011-12-15

  Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物，如本说明书中所定义的，含有它们的组合物以及制备这种化合物的方法。本文还提供了治疗可通过抑制PDE10治疗的疾病或疾病的方法，例如肥胖症，亨廷顿病，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症等。
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Dominguez Celia

  公开号：US20140329816A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一个或多个药学可接受载体的制药组合物。本文描述了治疗对KMO活性抑制有反应的某些疾病和疾病的患者的方法，包括向这些患者投予至少一种化学实体的数量，以减少疾病或疾病的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿病。还描述了治疗方法，包括单独使用至少一种化学实体作为活性剂，或与一个或多个其他治疗剂联合使用至少一种化学实体。还提供了筛选能够抑制KMO活性的化合物的方法。